- |||||||||| Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Neoadjuvant Combination Immunotherapy for Stage III Melanoma (clinicaltrials.gov) - May 1, 2024
P2, N=28, Recruiting,
Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2024 --> Jun 2026
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark. (clinicaltrials.gov) - May 1, 2024
P=N/A, N=1, Completed,
N=100 --> 42 Active, not recruiting --> Completed | N=580 --> 1 | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
- |||||||||| cyclophosphamide / Generic mfg., bendamustine / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date, Post-transplantation: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant (clinicaltrials.gov) - May 1, 2024
P1/2, N=25, Recruiting,
Trial completion date: Jan 2032 --> Sep 2031 | Trial primary completion date: Apr 2027 --> Dec 2026 N=40 --> 25 | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- |||||||||| Imlygic (talimogene laherparepvec) / Amgen
Trial termination, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - May 1, 2024
P1, N=3, Terminated,
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Inadequate accrual rate
- |||||||||| astegolimab (RG 6149) / Amgen, Roche
Approaches to COPD care: Targeting the ST2 receptor and IL-33 pathway as a potential option for patients at risk of exacerbating (Hilton Bayfront - Sapphire Ballroom) - Apr 30, 2024 - Abstract #ATS2024ATS_9712;
This educational event presents the latest scientific thinking in COPD care. Gain knowledge through educational presentations that bring to life: -The COPD patient: immunology, pathophysiology, and psychological burden -Astegolimab,* an investigational monoclonal antibody, potentially targeting the ST2 receptor and IL-33 pathway -The Genentech and Roche commitment to diversity in research *Astegolimab and its uses are investigational and have not been approved by the US Food and Drug Administration.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab in Adults With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Efficacy and Safety From the Phase 2a COURSE Study (San Diego Convention Center, Ballroom 20A (Upper Level)) - Apr 30, 2024 - Abstract #ATS2024ATS_9665;
P2
Gain knowledge through educational presentations that bring to life: -The COPD patient: immunology, pathophysiology, and psychological burden -Astegolimab,* an investigational monoclonal antibody, potentially targeting the ST2 receptor and IL-33 pathway -The Genentech and Roche commitment to diversity in research *Astegolimab and its uses are investigational and have not been approved by the US Food and Drug Administration. Tezepelumab reduced the overall rate of moderate or severe COPD exacerbations (primary endpoint), but statistical significance versus placebo was not achieved; greater reductions were observed in patients with BEC ?150 cells/
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Journal: Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim. (Pubmed Central) - Apr 30, 2024
This comprehensive study of long-term effects of filgrastim in unrelated donors of peripheral blood stem cells provides strong evidence that donors who receive filgrastim are not at increased risk of these events compared to bone marrow donors. It also provides reassurance to current donors undergoing stem cell mobilization as well as individuals considering joining stem cell registries such as NMDP.
- |||||||||| Krazati (adagrasib) / BMS, MRTX1133 / BMS, Lumakras (sotorasib) / Amgen
Review, Journal: Targeting KRAS in pancreatic cancer. (Pubmed Central) - Apr 30, 2024
The other KRAS mutations may be targeted indirectly via inhibition of the cognate guanosine exchange factor (GEF) Son of Sevenless 1 that drives KRAS. These agents seem to provide the means to target the most frequent KRAS mutations in PDAC and to improve patient outcomes.
- |||||||||| Krystexxa (pegloticase) / Amgen
Trial primary completion date: A Phase 4, Open-label Study of KRYSTEXXA (clinicaltrials.gov) - Apr 30, 2024
P4, N=50, Completed,
The PDI for all Neulasta Trial primary completion date: Oct 2023 --> May 2023
- |||||||||| namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Enrollment closed, Trial completion date, Trial primary completion date: RESOLVE-Lung: A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis (clinicaltrials.gov) - Apr 30, 2024
P2, N=107, Active, not recruiting,
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: May 2024 --> Dec 2024
- |||||||||| Lumakras (sotorasib) / Amgen
Trial completion, Trial completion date, Trial primary completion date: ROSIE: Rivaroxaban Sotorasib Interaction Study (clinicaltrials.gov) - Apr 30, 2024
P4, N=21, Completed,
Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: May 2024 --> Dec 2024 Recruiting --> Completed | Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Nov 2024 --> Mar 2024
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan (clinicaltrials.gov) - Apr 30, 2024
P=N/A, N=688, Completed,
Recruiting --> Completed | Trial completion date: Nov 2024 --> Mar 2024 | Trial primary completion date: Nov 2024 --> Mar 2024 Active, not recruiting --> Completed | Trial completion date: May 2025 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Feb 2024
- |||||||||| Review, Journal: Advancements in biologic therapy in eosinophilic asthma. (Pubmed Central) - Apr 29, 2024
Biological therapy for asthma targeting the IgE, IL-4, IL-5, IL-13, and TSLP pathways are shown to have benefit for the treatment of eosinophilic asthma, as exemplified in real world studies. When choosing the right biological agent factors such as phenotype, comorbidities, and cost-effectiveness of the biologic agent must be taken into consideration.
- |||||||||| Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Review, Journal: Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children. (Pubmed Central) - Apr 29, 2024
For children, evolocumab has been registered from the age of 10?years old and alirocumab from the age of 8?years old. The costs of these new agents are much higher than oral therapy, which makes it important to only use them in a selected patient population.
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Journal: Multifocal leukoencephalopathy in a (Pubmed Central) - Apr 29, 2024
This case report illustrates an important example of multifocal leukoencephalopathy induced by the combined use of etanercept and MTX, which resolved with high-dose corticosteroid. With the recent emphasis on various biologic agents for treatment of RA, our case highlights the importance of identifying leukoencephalopathy that may be induced by various biologics.
- |||||||||| Review, Journal: New Pharmacotherapeutic Classes for the Management of Heart Failure: A Narrative Review. (Pubmed Central) - Apr 29, 2024
We focus on vericiguat, omecamtiv mecarbil, ularitide, and serelaxin, and thoroughly examine their efficacy and safety profiles while summarizing the clinical trials of the drugs. There is a need for more long-term studies comparing the efficacy of these medications to the conventional ones.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
New P1 trial: A Study of TEPEZZA (clinicaltrials.gov) - Apr 28, 2024
P1, N=16, Completed,
- |||||||||| Fruzaqla (fruquintinib) / Takeda
Review, Journal, Metastases: Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? (Pubmed Central) - Apr 28, 2024
Fruquintinib, a tyrosine kinase inhibitor, has been shown to be effective in heavily pretreated mCRC progressing to trifluridine-tipiracil (FTD/TPI) or regorafenib or both...These results led to FDA approval of fruquintinib for pretreated mCRC patients who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy...However, an optimal sequence of treatments is yet to be defined. In this review, we propose an algorithm for later lines of treatment to integrate fruquintinib as a standard of care together with the new therapeutic combinations that recently showed clinical benefit for chemorefractory mCRC, in both molecularly selected (e.g. KRASG12C or HER2 amplification) and in non-oncogenic driven patients.
- |||||||||| ivabradine / Generic mfg.
Journal: Clinical implication of ivabradine therapy in patients receiving hemodialysis. (Pubmed Central) - Apr 28, 2024
In this review, we propose an algorithm for later lines of treatment to integrate fruquintinib as a standard of care together with the new therapeutic combinations that recently showed clinical benefit for chemorefractory mCRC, in both molecularly selected (e.g. KRASG12C or HER2 amplification) and in non-oncogenic driven patients. No abstract available
- |||||||||| Kepivance (palifermin) / SOBI, Amgen, avasopasem manganese (GC4419) / Galera Therap, dusquetide (SGX942) / Soligenix
Clinical, P3 data, Journal: Comparisons of successful and failed Phase III trials of drugs and biologicals tested for mitigation of oral mucositis in patients being treated with radiotherapy with or without concomitant chemotherapy for cancers of the head and neck. (Pubmed Central) - Apr 28, 2024
We found that differences in the level of sponsor funding, patient inclusion criteria including radiation source and concomitant chemotherapy regimen, and concordance of primary efficacy outcomes between Phase II and Phase III trials influenced outcomes. To properly design clinical trials for OM in HNC patients, it is important that researchers and sponsors take note of specific study characteristics associated with success or failure, particularly with Phase III trials where the risks and costs are the highest.
- |||||||||| Inlyta (axitinib) / Pfizer, Stivarga (regorafenib) / Bayer
Review, Journal: Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment. (Pubmed Central) - Apr 28, 2024
Curcumin alone led to dose-dependent responses and when combined with BYL719, positive effects were revealed, as they were when it was combined with MK-1775 or PD-0332991, suggesting a potential use of some of these combinations for HPV+ OPSCC. While certain therapies hold promise for GBM, future research should prioritize personalized medicine and innovative strategies for improved treatment outcomes.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal: Tezepelumab: patient selection and place in therapy in severe asthma. (Pubmed Central) - Apr 28, 2024
Therefore, it is necessary to identify clinical features of patients who can benefit from an upstream targeted therapy such as anti-thymic stromal lymphopoietin. The aims of this narrative review are to understand the role of alarmins in asthma pathogenesis and epithelial dysfunction, examine the rationale underlying the indication of TZP treatment in severe asthma, summarise the results of clinical studies, and recognise the specific characteristics of patients potentially eligible for TZP treatment.
|
